Abstract
Cyclosporin A, an potent immunosuppressant, has been known to be one of the modulators of drug resistance as well as a cytostatic drug. Despite many attempts to basic or clinical application of cyclosporin A, there are few reports on the inhibition of brain tumor cells. In the present experiment, the possibility of cyclosporin A as synergic adjuvant was investigated by MTT assay, [3H] thymidine uptake and through flowcytometric anaysis. Sole treatment of cyclosporin A on the CRT and CH235-MG glioma cell line revealed dose dependent cytotoxicity within a range of tested dose. Combined treatment of cyclosporin A with ACNU, BCNU and hydroxyurea on various glioma cancer cell line led to a significant synergistic cytotoxicity as well as inhibition of DNA synthesis with dose-dependency. In addition, cyclosporin A alone or combined treatment caused discernible changes of cell cycle in the tested cells. These data provide that cyclosporin A could potentiate the effect of nitrosourea compounds in vitro on human glioma cells.
| Original language | English |
|---|---|
| Pages (from-to) | 379-383 |
| Number of pages | 5 |
| Journal | Archives of Pharmacal Research |
| Volume | 20 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 1997 Jan 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Molecular Medicine
- Drug Discovery
- Organic Chemistry
Cite this
}
The effect of cyclosporin A on the growth of human glioma cell lines. / Pyen, Jhin Soo; Kim, Soo-Ki; Choi, Sun Ju; Park, Yoon Sun; Cho, Hyun Chul; Han, Young Pyo.
In: Archives of Pharmacal Research, Vol. 20, No. 4, 01.01.1997, p. 379-383.Research output: Contribution to journal › Article
TY - JOUR
T1 - The effect of cyclosporin A on the growth of human glioma cell lines
AU - Pyen, Jhin Soo
AU - Kim, Soo-Ki
AU - Choi, Sun Ju
AU - Park, Yoon Sun
AU - Cho, Hyun Chul
AU - Han, Young Pyo
PY - 1997/1/1
Y1 - 1997/1/1
N2 - Cyclosporin A, an potent immunosuppressant, has been known to be one of the modulators of drug resistance as well as a cytostatic drug. Despite many attempts to basic or clinical application of cyclosporin A, there are few reports on the inhibition of brain tumor cells. In the present experiment, the possibility of cyclosporin A as synergic adjuvant was investigated by MTT assay, [3H] thymidine uptake and through flowcytometric anaysis. Sole treatment of cyclosporin A on the CRT and CH235-MG glioma cell line revealed dose dependent cytotoxicity within a range of tested dose. Combined treatment of cyclosporin A with ACNU, BCNU and hydroxyurea on various glioma cancer cell line led to a significant synergistic cytotoxicity as well as inhibition of DNA synthesis with dose-dependency. In addition, cyclosporin A alone or combined treatment caused discernible changes of cell cycle in the tested cells. These data provide that cyclosporin A could potentiate the effect of nitrosourea compounds in vitro on human glioma cells.
AB - Cyclosporin A, an potent immunosuppressant, has been known to be one of the modulators of drug resistance as well as a cytostatic drug. Despite many attempts to basic or clinical application of cyclosporin A, there are few reports on the inhibition of brain tumor cells. In the present experiment, the possibility of cyclosporin A as synergic adjuvant was investigated by MTT assay, [3H] thymidine uptake and through flowcytometric anaysis. Sole treatment of cyclosporin A on the CRT and CH235-MG glioma cell line revealed dose dependent cytotoxicity within a range of tested dose. Combined treatment of cyclosporin A with ACNU, BCNU and hydroxyurea on various glioma cancer cell line led to a significant synergistic cytotoxicity as well as inhibition of DNA synthesis with dose-dependency. In addition, cyclosporin A alone or combined treatment caused discernible changes of cell cycle in the tested cells. These data provide that cyclosporin A could potentiate the effect of nitrosourea compounds in vitro on human glioma cells.
UR - http://www.scopus.com/inward/record.url?scp=20544478179&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=20544478179&partnerID=8YFLogxK
U2 - 10.1007/BF02976205
DO - 10.1007/BF02976205
M3 - Article
C2 - 18975184
AN - SCOPUS:20544478179
VL - 20
SP - 379
EP - 383
JO - Archives of Pharmacal Research
JF - Archives of Pharmacal Research
SN - 0253-6269
IS - 4
ER -